Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Phase 3

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: BGB-16673
Drug: Bendamustine
Drug: Rituximab
Drug: Methylprednisolone

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-20

Lead Sponsor: BeiGene

Target Recruit Count: 150

Registration Number: NCT06970743

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Phase 2

Not yet recruiting

Conditions: Follicular Lymphoma Grade 3A

Interventions: Drug: Obinutuzumab
Drug: CHOP
Drug: Bendamustine

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 133

Registration Number: NCT06961500

Locations: 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

Not Applicable

Not yet recruiting

Conditions: Waldenström's Macroglobulinemia (WM)

Interventions: Drug: Zanubrutinib
Drug: Bendamustine + Rituximab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-30

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 104

Registration Number: NCT06942507

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

Phase 3

Not yet recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Golcadomide
Drug: Rituximab
Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone/Prednisolone
Drug: Bendamustine

First Posted Date: 2025-04-04

Last Posted Date: 2025-05-07

Lead Sponsor: Celgene

Target Recruit Count: 400

Registration Number: NCT06911502

Locations: 🇺🇸
Local Institution - 0214, Tampa, Florida, United States
🇵🇱
Local Institution - 0189, Łódź, Łódzkie, Poland
🇺🇸
Local Institution - 0008, Jacksonville, Florida, United States

and more 114 locations

BRAZAN Trial in Frontline MCL

Phase 2

Not yet recruiting

Conditions: Mantle Cell Lymphoma
Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Cytarabine
Drug: Sonrotoclax
Drug: Zanubrutinib

First Posted Date: 2025-03-03

Last Posted Date: 2025-03-03

Lead Sponsor: Christine Ryan

Target Recruit Count: 60

Registration Number: NCT06854003

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Phase 3

Recruiting

Conditions: CLL
Chronic Lymphocytic Leukemia

Interventions: Drug: BGB-16673
Drug: Bendamustine
Drug: Idelalisib
Drug: Rituximab
Drug: Venetoclax

First Posted Date: 2025-02-26

Last Posted Date: 2025-05-16

Lead Sponsor: BeiGene

Target Recruit Count: 250

Registration Number: NCT06846671

Locations: 🇳🇿
North Shore Hospital, Auckland, New Zealand
🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

and more 96 locations

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4

Not yet recruiting

Conditions: Hodgkin Lymphoma (Category)

Interventions: Drug: Brentuximab Vedotin (Bv)
Drug: Sintilimab
Drug: Tislelizumab
Drug: Bendamustine

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-07

Lead Sponsor: Xiuhua Sun

Target Recruit Count: 100

Registration Number: NCT06761911

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Phase 2

Not yet recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Zuberitamab
Drug: Bendamustine

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT06757894

Locations: 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Phase 2

Not yet recruiting

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Zanubrutinib
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2024-08-20

Last Posted Date: 2024-12-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 55

Registration Number: NCT06561347

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Phase 2

Not yet recruiting

Conditions: Indolent Non-hodgkin Lymphoma
Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2024-08-16

Last Posted Date: 2025-01-06

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT06557330

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy